Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Therapy
  4. Fast Track Articles
  5. Fast Track Article
image of Advances in Antiviral Therapies: Exploring Amphiphilic Small Molecules for Mpox Virus Treatment

Abstract

Mpox is an emerging zoonotic viral infection caused by the Monkeypox virus that has become a global health threat. Though vaccines for smallpox are available and used, therapeutics are scarce for Mpox, and increasing drug-resistant strains are found. Among recent advances in antiviral therapy, amphiphilic small molecules have been found, which could potentially serve as inhibitors of viral replication. This editorial describes the challenges presented by the Mpox virus as it evolves over time and delves deeper into more recent studies based on computational drug design and nanoassembly. In this regard, small amphiphilic molecules have established their potential to inhibit viral entry and replication through interaction with viral envelope proteins. This editorial also describes the current state of research into such small molecules. It underlines their promise in the potential struggle against Mpox and explores their mechanisms of action, therapeutic efficacy, and prospects for clinical application.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855364446250208172119
2025-02-14
2025-06-26

  • From This Site

    /content/journals/cdth/10.2174/0115748855364446250208172119
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Wang J. Nguyen L. Volante V. Daniel J. Preuss C. Mpox: New challenges with the disease. Rising Contagious Diseases: Basics Management, and Treatments John Wiley & Sons, Inc. 2024 20 30 10.1002/9781394188741.ch3
    [Google Scholar]
  2. Chhabra M. Shanthamurthy C.D. Kumar N.V. Mardhekar S. Vishweshwara S.S. Wimmer N. Modhiran N. Watterson D. Amarilla A.A. Cha J.S. Beckett J.R. De Voss J.J. Kayal Y. Vlodavsky I. Dorsett L.R. Smith R.A.A. Gandhi N.S. Kikkeri R. Ferro V. Amphiphilic heparinoids as potent antiviral agents against SARS-CoV-2. J. Med. Chem. 2024 67 14 11885 11916 10.1021/acs.jmedchem.4c00487 38995734
    [Google Scholar]
  3. Ibrahim H. Eranki A. Mpox: An emerging global orthopoxvirus outbreak. Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century. Springer 2024 143 153
    [Google Scholar]
  4. Jiang L. Xu A. Guan L. Tang Y. Chai G. Feng J. A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies. Exploration. Wiley Online Library 2024 20230112
    [Google Scholar]
  5. Gigante C.M. Takakuwa J. McGrath D. Kling C. Smith T.G. Peng M. Wilkins K. Garrigues J.M. Holly T. Barbian H. Kittner A. Haydel D. Ortega E. Richardson G. Hand J. Hacker J.K. Espinosa A. Haw M. Kath C. Bielby M. Short K. Johnson K. De La Cruz N. Davidson W. Hughes C. Green N.M. Baird N. Rao A.K. Hutson C.L. Notes from the field : Mpox cluster caused by tecovirimat-resistant monkeypox virus — Five states, october 2023–february 2024. MMWR Morb. Mortal. Wkly. Rep. 2024 73 40 903 905 10.15585/mmwr.mm7340a3 39388389
    [Google Scholar]
  6. National Institutes of Health The Antiviral Tecovirimat Is Safe but Did Not Improve Clade I Mpox Resolution in Democratic Republic of the Congo. Annapolis, MD, USA National Institutes of Health Report 2024
    [Google Scholar]
  7. Shah B.M. Modi P. Breaking barriers: Current advances and future directions in Mpox therapy. Curr. Drug Targets 2024 25 1 62 76 10.2174/0113894501281263231218070841 38151842
    [Google Scholar]
  8. Pasikhova Y. Antiviral agents: Cidofovir and brincidofovir. Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century. Springer 2024 251 277
    [Google Scholar]
  9. Smith T.G. Gigante C.M. Wynn N.T. Matheny A. Davidson W. Yang Y. Condori R.E. O’Connell K. Kovar L. Williams T.L. Yu Y.C. Petersen B.W. Baird N. Lowe D. Li Y. Satheshkumar P.S. Hutson C.L. Tecovirimat resistance in mpox patients, United States, 2022–2023. Emerg. Infect. Dis. 2023 29 12 2426 2432 10.3201/eid2912.231146 37856204
    [Google Scholar]
  10. Kumar S. Guruparan D. Karuppanan K. Kumar K.J.S. Comprehensive insights into monkeypox (mpox): Recent advances in epidemiology, diagnostic approaches and therapeutic strategies. Pathogens 2024 14 1 1 10.3390/pathogens14010001 39860962
    [Google Scholar]
  11. Alameer R.M. Yamani A. Al-Saud A. Alsobayeg S. Alamro B. Alali A. Hammad E. Shendi A.M. Almaghrabi R.S. The successful treatment of mpox with brincidofovir in renal transplant recipients—a report of 2 cases. Int. J. Infect. Dis. 2024 143 107015 10.1016/j.ijid.2024.107015 38521447
    [Google Scholar]
  12. Wang J. Shahed-AI-Mahmud M. Chen A. Li K. Tan H. Joyce R. An overview of antivirals against monkeypox virus and other orthopoxviruses. J. Med. Chem. 2023 66 7 4468 4490 10.1021/acs.jmedchem.3c00069 36961984
    [Google Scholar]
  13. Sagdat K. Batyrkhan A. Kanayeva D. Exploring monkeypox virus proteins and rapid detection techniques. Front. Cell. Infect. Microbiol. 2024 14 1414224 10.3389/fcimb.2024.1414224 38863833
    [Google Scholar]
  14. de Araújo L.P. de Melo Santos N.C. Corsetti P.P. de Almeida L.A. Immunoinformatic approach for rational identification of immunogenic peptides against host entry and/or exit Mpox proteins and potential multiepitope vaccine construction. J. Infect. Dis. 2024 229 Suppl. 2 S285 S292 10.1093/infdis/jiad443 37804521
    [Google Scholar]
  15. Paul D. Saha S. Basu S. Chakraborti T. Computational analysis of pathogen-host interactome for fast and low-risk in-silico drug repurposing in emerging viral threats like Mpox. Sci. Rep. 2024 14 1 18736 10.1038/s41598‑024‑69617‑8 39134619
    [Google Scholar]
  16. Pyrć K. Milewska A. Duran E.B. Botwina P. Dabrowska A. Jedrysik M. Benedyk M. Lopes R. Arenas-Pinto A. Badr M. Mellor R. Kalber T.L. Fernandez-Reyes D. Schätzlein A.G. Uchegbu I.F. SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray. Sci. Rep. 2021 11 1 20012 10.1038/s41598‑021‑99404‑8 34625610
    [Google Scholar]
  17. Das P.P. Sengupta S. Balram D. Lian K-Y. Azizov S. Neogi U.K. Recent advancements of nanoparticles for antiviral therapy. Adv. Nat. Sci. Nanosci. Nanotechnol. 2024 15 4 043001 10.1088/2043‑6262/1/4/043001
    [Google Scholar]
  18. Dash S.R. Kundu C.N. Advances in nanomedicine for the treatment of infectious diseases caused by viruses. Biomater. Sci. 2023 11 10 3431 3449 10.1039/D2BM02066A 36974930
    [Google Scholar]
  19. Rocha B. de Morais L.A. Viana M.C. Carneiro G. Promising strategies for improving oral bioavailability of poor water-soluble drugs. Expert Opin. Drug Discov. 2023 18 6 615 627 10.1080/17460441.2023.2211801 37157841
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855364446250208172119
Loading

  • Article Type:     Editorial
Keywords: Tecovirimat ; amphiphilic small molecules ; antiviral ; zoonotic viral ; viral envelope ; Mpox virus ; drug resistance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test